SCHEMBL344155

SCHEMBL344155

O=c1c(O)c(-c2cccc(O)c2)oc2cc(O)ccc12

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.81
KMT2A Q03164 12/20 0.81
CYP3A4 P08684 12/20 0.81
KDM4E B2RXH2 9/20 0.81
HSD17B10 Q99714 8/20 0.81
MAPT P10636 8/20 0.81
ALOX15 P16050 6/20 0.81
CASP1 P29466 4/20 0.81
CASP7 P55210 4/20 0.81
CYP2C9 P11712 8/20 0.78
ALDH1A1 P00352 7/20 0.78
HPGD P15428 7/20 0.78
CYP2C19 P33261 5/20 0.78
CYP2D6 P10635 4/20 0.78
DHFR P00374 1/20 0.78
CYP1A2 P05177 1/20 0.78
KCNH2 Q12809 1/20 0.78
MAPK1 P28482 7/20 0.75
TP53 P04637 6/20 0.75
RECQL P46063 3/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31675772 1.00 MEN1 (0.81) MEN1KMT2ACYP3A4KDM4EHSD17B10
Resokaempferol SCHEMBL4728192 0.91 MEN1 (0.82) MEN1KMT2ACYP3A4KDM4EHSD17B10
3,7-Dihydroxyflavone SCHEMBL29625323 0.89 CYP3A4 (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10
3,7-Dihydroxyflavone SCHEMBL2396684 0.89 CYP3A4 (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10
SCHEMBL17356386 0.89 MAPT (0.71) MEN1KMT2ACYP3A4KDM4EHSD17B10
SCHEMBL1628821 0.88 DHFR (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10
SCHEMBL345657 0.88 MEN1 (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10
SCHEMBL25238273 0.87 CYP1A2 (0.76) MEN1KMT2ACYP3A4KDM4EHSD17B10
Resokaempferol SCHEMBL30873045 0.86 MEN1 (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10
Resokaempferol SCHEMBL344710 0.86 MEN1 (1.00) MEN1KMT2ACYP3A4KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897637-B2 Methods of using flavonoids to enhance memory THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2011-03-01 US claimed
WO-2008011538-A2 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-01-24 WO claimed
US-20080021096-A1 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2008-01-24 US claimed
WO-2007083904-A1 C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2007-07-26 WO claimed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
US-20220387542-A1 PROTECTIVE EFFECTS OF OIL PALM COMPOSITION ON ALZHEIMER'S DISEASE MALAYSIAN PALM OIL BOARD (MY) 2022-12-08 US disclosed
US-11517607-B2 Protective effects of oil palm composition on Alzheimer's disease MALAYSIAN PALM OIL BOARD (MY) 2022-12-06 US disclosed
US-20220193087-A1 COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION 2022-06-23 US disclosed
US-11110097-B2 Combination therapies for the treatment of alzheimer's disease and related disorders THE GENERAL HOSPITAL CORPORATION (US) 2021-09-07 US disclosed
EP-3057437-B1 PROTECTIVE EFFECTS OF OIL PALM COMPOSITION ON ALZHEIMER'S DISEASE MALAYSIAN PALM OIL BOARD (MY) 2020-10-07 EP disclosed
US-20200085903-A1 Protective Effects of Oil Palm Composition on Alzheimer's Disease MALAYSIAN PALM OIL BOARD (MY) 2020-03-19 US disclosed
US-20200078366-A1 COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION 2020-03-12 US disclosed
WO-2008011538-A2 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-01-24 WO disclosed
WO-2008011538-A2 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2008-01-24 WO disclosed
US-20080021096-A1 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2008-01-24 US disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
WO-2007083904-A1 C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2007-07-26 WO disclosed
WO-2007083904-A1 C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2007-07-26 WO disclosed
WO-2006030322-A2 USE OF FLA VONE/FLA VANONE DERIVATIVES FN THE TREATMENT OR PREVENTION OF RESPIRATORY CONDITIONS UNIVERSITY OF MANITOBA (CA) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200078366-A1 COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS APP, SNCA, MAPT MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 MEN1 4281/4885KMT2A 4362/4885CYP3A4 17/4885
US-11110097-B2 Combination therapies for the treatment of alzheimer's disease and related disorders APP, SNCA, MAPT MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885
US-20080021096-A1 METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY FOS, CREBBP, CREB1 MEN1 3520/4885KMT2A 1152/4885CYP3A4 4468/4885
US-20220193087-A1 COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS APP, SNCA, MAPT MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.